<DOC>
	<DOCNO>NCT00851773</DOCNO>
	<brief_summary>This trial conduct Europe . The aim clinical trial ass compare safety tolerability , assessed adverse event multiple subcutaneous dos NN9535 healthy male Japanese Caucasian subject .</brief_summary>
	<brief_title>Safety , Tolerability , Profile Action Drug Body NN9535 Healthy Male Japanese Caucasian Subjects</brief_title>
	<detailed_description />
	<criteria>For Caucasian Japanese volunteer follow applies : Informed consent obtain trialrelated activity Body weight 54 90 kg ( inclusive ) Body mass index ( BMI ) 18.5 24.9 kg/m2 ( inclusive ) HbA1c 6.0 % Subjects consider generally healthy base assessment medical history , physical examination clinical laboratory data screening , judge Investigator Subjects sexually active partner could pregnant willing require use barrier method contraception ( e.g . condom ) duration study 90 day follow last dose study medication Japanese passport holder , Japaneseborn parent , live outside Japan 5 year less Any clinical laboratory value deviate outside laboratory reference range unless consider clinically significant investigator Any abnormal ECG finding screen , consider clinically significant Investigator Presence history diabetes , cancer clinically significant cardiac , respiratory , metabolic , renal , hepatic , gastrointestinal , endocrinological , dermatological , venereal , haematological , neurological , psychiatric disease disorder , consider clinically significant Investigator Previous randomise trial ( applicable standby volunteer ) Blood pressure supine position screening , rest 5 min , stand position stand 1 min , consistently outside range 90 140 mmHg systolic 40 90 mmHg diastolic Heart rate supine position screening , rest 5 min , consistently 100 beats/min Alcohol intake within 48 hour prior screen admission ( examine alcohol breath test ) Hepatitis B surface antigen , Hepatitis C antibodies Human Immunodeficiency Virus ( HIV ) antibodies positive History significant allergy hypersensitivity Known suspect allergy trial product related product History drug alcohol abuse ( alcohol abuse define intake 21 unit ( U ) weekly : One unit alcohol equal 1/2 pint ( approximately 250 mL ) beer lager , one glass wine Japanese sake , 1/6 gill ( approximately 20 mL ) spirit ) Subjects smoke 10 cigarette , equivalent , per day unwilling refrain smoke whenever require trial procedure Use prescription drug within 3 week prior dose , nonprescription drug within 1 week prior dose except vitamin , mineral nutritional supplement Received investigational drug within 12 week prior plan first dose Subjects take part strenuous exercise within 48 hour prior first dose , due interference hepatic microsomal monooxygenase system . The Investigator SubInvestigator evaluate whether strenuous exercise undertaken Loss 400 mL blood total within last 12 week 200 mL blood total within last 4 week prior first dose Subjects firstdegree relative diabetes mellitus Mental incapacity , unwillingness language barrier preclude adequate understanding cooperation Possibility subject comply protocol Subjects opinion Investigator SubInvestigator participate trial Subjects know history either Type 1 Type 2 diabetes mellitus exclude</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>